FDA declines approval of Summit’s lung cancer treatment

Résumé détaillé

Summit Therapeutics says FDA declines ivonescimab plus chemotherapy approval for advanced lung cancer, citing insufficient evidence of longer survival.

Summit Therapeutics (SMMT) said Sunday that the U.S. Food and Drug Administration declined to approve ivonescimab combined with chemotherapy for certain patients with advanced lung cancer, citing insufficient evidence that the treatment helps patients live longer.

Début de l'article, extrait de Seeking Alpha. Pour lire la suite, ouvrez l'article chez le média.